Why is Stryker (SYK) stock up today?

Stryker shares climbed 1.73% to $316.44 on July 16, 2026, recovering from the prior session's sector-wide pullback. The primary catalyst is a favorable read-through from Johnson & Johnson's quarterly earnings report, which, despite J&J itself slipping on its results, prompted analysts to argue the underlying data bodes well for medical-device peers including Stryker, Intuitive Surgical, and Abbott — companies exposed to similar procedure-volume and hospital-spending trends.

The medical-device group had sold off the previous day, with a group of medical giants including Intuitive Surgical and Stryker falling together. That decline appears to have been short-lived, as the sector reassessed the J&J report and found constructive signals for procedural-care companies. Stryker, which sells orthopedic implants, surgical equipment, and neurotechnology, benefits from rising elective-surgery volumes — the same lever that analysts cited when noting J&J's report as a positive signal for the group.

The broader market offered a mixed backdrop: the S&P 500 gained 0.38% while the tech-heavy QQQ slipped 0.27%, suggesting the session's strength was concentrated in non-tech sectors like healthcare rather than a broad risk-on rally. Macro conditions remain relevant: CPI data released earlier this week showed headline inflation at 3.8% year-over-year (down from 4.2%), which eases pressure on the Federal Reserve and can support rate-sensitive sectors including healthcare.

Stryker's next earnings report is scheduled for July 30, 2026. In the most recent quarter, the company reported revenue of $6.02 billion and earnings per share of $2.60, which came in below the $2.98 analyst estimate. The stock carries a trailing price-to-earnings ratio of 36.0 and a forward P/E of 18.9, against a market capitalization of approximately $121.3 billion. Revenue growth stood at 2.6% and earnings growth at 14.2% in the most recent period.